Beijing Double-Crane

CR Double-Crane is a prominent Chinese pharmaceutical company and a core subsidiary of the China Resources Pharmaceutical Group. The company operates a diverse portfolio focusing on five main areas: cardiovascular, endocrine, nephrology, pediatrics, and large-volume parenterals (IV infusions). As one of the largest infusion manufacturers in China, it maintains a dominant market share and a robust distribution network across the country. In recent years, the company has transitioned from a traditional generic manufacturer to an innovation-driven enterprise, notably through its partnership to produce the COVID-19 antiviral Azvudine and its investment in high-end generic consistency evaluations.